Impact of HER2‐low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR‐positive/HER2‐negative metastatic breast cancer: A prospective study

MLA

Yun Wu, et al. “Impact of HER2‐low Expression on the Efficacy of Endocrine Therapy with or without CDK4/6 Inhibitor in HR‐positive/HER2‐negative Metastatic Breast Cancer: A Prospective Study.” Thoracic Cancer, vol. 15, no. 12, Apr. 2024, pp. 965–73. EBSCOhost, https://doi.org/10.1111/1759-7714.15282.

APA

Yun Wu, Hongnan Mo, Hangcheng Xu, Yan Wang, Jiayu Wang, Fei Ma, & Binghe Xu. (2024). Impact of HER2‐low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR‐positive/HER2‐negative metastatic breast cancer: A prospective study. Thoracic Cancer, 15(12), 965–973. https://doi.org/10.1111/1759-7714.15282

Chicago

Yun Wu, Hongnan Mo, Hangcheng Xu, Yan Wang, Jiayu Wang, Fei Ma, and Binghe Xu. 2024. “Impact of HER2‐low Expression on the Efficacy of Endocrine Therapy with or without CDK4/6 Inhibitor in HR‐positive/HER2‐negative Metastatic Breast Cancer: A Prospective Study.” Thoracic Cancer 15 (12): 965–73. doi:10.1111/1759-7714.15282.